Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Busulfan (conditioning for ALLO Transplant)Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
100%(1 trials)

Phase Distribution

Phase 2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

completed150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_2

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

NCT06802315
completedphase_2

Tandem Auto-Allo Transplant for Lymphoma

NCT01181271

Clinical Trials (2)

Showing 2 of 2 trials
NCT06802315Phase 2

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

Recruiting
NCT01181271Phase 2

Tandem Auto-Allo Transplant for Lymphoma

Completed

All 2 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
2